beta-blocking agent


Also found in: Thesaurus.
Related to beta-blocking agent: cholinergic blocking agent
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.beta-blocking agent - any of various drugs used in treating hypertension or arrhythmiabeta-blocking agent - any of various drugs used in treating hypertension or arrhythmia; decreases force and rate of heart contractions by blocking beta-adrenergic receptors of the autonomic nervous system
acebutolol, Sectral - an oral beta blocker (trade name Sectral) used in treating hypertension
atenolol, Tenormin - an oral beta blocker (trade name Tenormin) used in treating hypertension and angina; has adverse side effects (depression and exacerbation of congestive heart failure etc.)
blocking agent, blocker - a class of drugs that inhibit (block) some biological process
carvedilol - beta blocker that can reduce the progression of heart failure in individuals whose disease is not advanced
Brevibloc, esmolol - intravenous beta blocker (trade name Brevibloc) that acts for only a short time; used primarily for cardiac arrhythmias
Lopressor, metoprolol - beta blocker (trade name Lopressor) used in treating hypertension and angina and arrhythmia and acute myocardial infarction; has adverse side effects (depression and exacerbation of congestive heart failure etc.)
Corgard, nadolol - a beta-adrenergic blocking agent (trade name Corgard) that is used to treat hypertension and angina
pindolol, Visken - an oral beta blocker (trade name Visken) used in treating hypertension
Inderal, propanolol - the first beta blocker (trade name Inderal) used in treating hypertension and angina pectoris and essential tremor
Blocadren, timolol - a beta blocker (trade name Blocadren) administered after heart attacks
References in periodicals archive ?
This beta-blocking agent is banned only in certain sports such as shooting and archery which require great control.
Furthermore, we believe alpha-2C-receptor genetic biomarkers may be combined with the already reported beta1 receptor position 389 genetic biomarkers to define which patients are most likely to respond to this pharmacologically unique beta-blocking agent.